220389-17-3

Basic information

• Product Name: Ethyl 4-cyano-2-Methylbenzoate
• Synonyms: Ethyl 4-cyano-2-Methylbenzoate
• CAS NO: 220389-17-3
• Molecular Formula: C₁₁H₁₁NO₂
• Molecular Weight: 189.21054
• Mol File: 220389-17-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 316.5±30.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethyl 4-cyano-2-Methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-cyano-2-Methylbenzoate(220389-17-3)
• EPA Substance Registry System: Ethyl 4-cyano-2-Methylbenzoate(220389-17-3)

Safety Data

• Hazardous Substances Data: 220389-17-3(Hazardous Substances Data)

Upstream product

• 544-92-3 copper(I) cyanide 
• 151-50-8 potassium cyanide 
• 220389-34-4 ethyl 4-bromo-2-methylbenzoate 
• 74450-59-2 4-amino-2-methyl-benzoic acid ethyl ester 

Downstream Products

• 1015230-78-0 4-(N-Hydroxycarbamimidoyl)-2-methyl-benzoic acid ethyl ester 
• 1015230-77-9 4-(imino-methoxycarbonylaminomethyl)-2-methyl-benzoic acid ethyl ester 
• 1975-53-7 4-Cyano-2-methylbenzoic acid 

Relevant articles and documents

Fibrinogen receptor antagonists and their use

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

N-acylamino acid amide compounds and intermediates for preparation thereof

The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.